Phase II study of E7070 in patients with metastatic melanoma

• Published in: Annals of oncology Vol. 16; no. 1; pp. 158 - 161
• Main Authors: Smyth, J. F., Aamdal, S., Awada, A., Dittrich, C., Caponigro, F., Schöffski, P., Gore, M., Lesimple, T., Djurasinovic, N., Baron, B., Ravic, M., Fumoleau, P., Punt, C. J. A.
• Format: Journal Article
• Language: English
• Published: Oxford Oxford University Press 01.01.2005
• Subjects: Adult; Aged; Antineoplastic agents; Biological and medical sciences; Dermatology; Disease Progression; Female; Humans; Infusions, Intravenous; Male; Medical sciences; Melanoma - drug therapy; Melanoma - pathology; Middle Aged; Pharmacology. Drug treatments; Skin Neoplasms - drug therapy; Skin Neoplasms - pathology; Sulfonamides - administration & dosage; Sulfonamides - adverse effects; Sulfonamides - therapeutic use; Treatment Outcome; Tumors of the skin and soft tissue. Premalignant lesions; Human; Treatment; Phase II trial; Malignant melanoma; Advanced stage; Malignant tumor; Metastasis
• ISSN: 0923-7534; 1569-8041
• DOI: 10.1093/annonc/mdi016

E7070 is a synthetic chloro-indolyl sulphonamide that is being developed as an anti cancer agent. In this phase II study, 28 patients with metastatic melanoma received 700 mg/m2 of E7070 as a 60-min infusion repeated every 3 weeks. Although therapy was well tolerated, with one patient receiving 14 courses of treatment, there were only minor responses on independent radiological review. E7070 does not warrant further development as a single agent for the treatment of metastatic melanoma.